[ad_1]
IN Moderna’s axin against COVID-19 produces antibodies that may be available in the body 90 days after vaccination, AFP reported, citing a publication in the scientific journal The New England Journal of Medicine.
Direction of the PCR test and after a positive rapid antigen result
The Modern Covid-19 vaccine, which was recently shown to be 94 percent effective, causes the human immune system to produce potent antibodies that last for at least three months, a study showed https://t.co/2uoQkg7K4i
– AFP news agency (@AFP) December 3, 2020
The duration of protection provided by the vaccine is undoubtedly longer, but this is the first data for a period of several months, validated independently of a scientific publication.
Kostadin Angelov: the vaccine will be administered only after informed consent
The 34 study participants will be followed for 13 months to see what the long-term protection is provided by the vaccine.
Scientists have identified the most common source of COVID-19 infection
Researchers at the National Institutes of Health tested the level of two types of coronavirus antibodies 90 days after the second dose of the vaccine, which is injected 28 days after the first dose.
The specialists observed a slight and expected decrease in the level of antibodies in the vaccinated study participants, but the level of antibodies remained high and exceeded the natural immunity observed in patients recovering from COVID-19.
How GPs will issue referrals for PCR
Additionally, no serious side effects were seen in phase one vaccine trials that began in March, according to the scientific publication.
A few days ago it became clear that the pharmaceutical company Moderna has requested the urgent approval of its vaccine against COVID-19 in the Food and Drug Administration of the United States.
According to the manufacturer, the full results of the last phase of the studies showed a 94.1% effectiveness of the vaccine, without serious concerns about its safety.
The company also intends to apply for approval in Europe.
The US regulator will consider the approval request at a meeting on December 17. The US administration has given Moderna $ 486 million to develop a vaccine against the new coronavirus. If approved, the vaccine will be available to Americans on December 21.
Moderna is the second company to request emergency approval of its vaccine. Pfizer filed documents for the same proceeding on November 20.
In both vaccines, the first doses will be injected into certain groups: medical personnel, front-line personnel, and people at risk.
More than 70 vaccines against the new coronavirus are being developed around the world. 11 of them, including those from Moderna and Pfizer, are in the large-scale clinical trial stage.
OVID-19: Decrease in new cases, but again more than 150 victims
Prof. Stoilova: Vaccines are the safest remedy against a pandemic
EU with warning after UK vaccine approval
The UK was the first in the world to approve the Pfizer / BioNTech vaccine against COVID-19
Is vaccination against COVID-19 possible in December?
A virologist explained how the Covid-19 vaccine works, if it is dangerous
[ad_2]
